Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32675244 | 1.00 | GRIN2B (0.54) | GRIN2BLTA4HBCHEACHEBACE1 | |
| SCHEMBL30164338 | 0.90 | LTA4H (0.62) | GRIN2BLTA4HBCHEACHEBACE1 | |
| SCHEMBL18290472 | 0.90 | LTA4H (0.62) | GRIN2BLTA4HBCHEACHEBACE1 | |
| SCHEMBL18792185 | 0.90 | LTA4H (0.62) | GRIN2BLTA4HBCHEACHEBACE1 | |
| SCHEMBL375264 | 0.89 | GRIN2B (0.62) | GRIN2BBCHEACHEBACE1MEN1 | |
| SCHEMBL23553927 | 0.85 | MEN1 (0.52) | MEN1KMT2A | |
| SCHEMBL20528646 | 0.85 | GRIN2B (0.56) | GRIN2BBCHEACHEBACE1MEN1 | |
| SCHEMBL12380 | 0.83 | ACHE (0.48) | LTA4HBCHEACHEBACE1MEN1 | |
| SCHEMBL375157 | 0.79 | MEN1 (0.75) | GRIN2BBCHEACHEBACE1MEN1 | |
| SCHEMBL16286711 | 0.79 | EGLN2 (0.44) | LTA4HMEN1RAB9AKMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499620-B1 | METHOD FOR THE PREPARATION OF CIS-4-AMINOTETRAHYDROFURAN-2-CARBOXYLATES | BAYER AG (DE) | 2026-02-18 | — | — | EP | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| CN-105073746-B | Substituted imidazopyridines as HDM2 inhibitors | 默沙东公司 | 2017-03-22 | — | — | CN | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| CN-105073746-A | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME | 2015-11-18 | — | — | CN | disclosed |
| CN-101863908-A | Oxacyclo-sulfamide spirocyclic medicament template and synthesis method thereof | WUXI APP SHANGHAI CO LTD | 2010-10-20 | — | — | CN | disclosed |
| US-7514573-B2 | Processes for the manufacture of chiral and racemic forms of 3-aminotetrahydrofurans, their salts and derivatives | SAMI LABS LTD (IN) | 2009-04-07 | — | — | US | disclosed |
| US-20080255377-A1 | reduction of diesters of aspartic acid, then cyclization with the aid of sulfonic acids, hydrolysis using a base to give 3-(S)-aminotetrahydrofuran as its hydrochloride or p-toluenesulfonate salt, or as base itself | MAJEED MUHAMMED | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255377-A1 | reduction of diesters of aspartic acid, then cyclization with the aid of sulfonic acids, hydrolysis using a base to give 3-(S)-aminotetrahydrofuran as its hydrochloride or p-toluenesulfonate salt, or as base itself | AASDHPPT, DNPEP, ASNS | GRIN2B 1833/4885LTA4H 574/4885BCHE 555/4885 |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | GRIN2B 928/4885LTA4H 2594/4885BCHE 4197/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | GRIN2B 874/4885LTA4H 2814/4885BCHE 4277/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | GRIN2B 928/4885LTA4H 2594/4885BCHE 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.